The US Food and Drug Administration on Monday approved the use of the experimental drug aducanumab for early phases of Alzheimer's disease -- despite an FDA advisory committee concluding last year ...
The pursuit of a cure for Alzheimer's disease is becoming an increasingly competitive and contentious quest, with recent ...
The FDA on Monday approved an experimental drug that aims to slow the progression of Alzheimer's disease, despite the fact that a key FDA panel late last year said that questions remain about its ...
At its November meeting, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) voted against Biogen's controversial Alzheimer's drug aducanumab (Aduhelm), ...
This article is part of “Innovations In: Alzheimer's Disease” an editorially independent special report that was produced with financial support from Eisai. One of neurologist Anelyssa D’Abreu’s least ...
PHILADELPHIA (WPVI) -- The Food & Drug Administration has approved a new drug for Alzheimer's Disease. It's the first in nearly twenty years but it comes with controversy and some experts advised ...
SAN DIEGO -- A company that claims to have the first drug to slow mental decline from Alzheimer's disease made its case to scientists Thursday but left them sharply divided over whether there's enough ...
CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...
Growth fueled by the increasing incidence of Alzheimer's disease, growing aging population, and continued development in ...
- Brain amyloid clearance (<24.1 Centiloids) was achieved in 37.9% of donanemab-treated participants compared with 1.6% of Aduhelm ® (aducanumab-avwa)-treated patients at 6 months - Donanemab reduced ...
CAMBRIDGE, Mass. -- Biogen Inc. said Tuesday it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback